Human Infection with Japanese Encephalitis Virus Genotype V, China, 2025.

Emerg Infect DisOct 1, 2026
Case ReportInfectious Diseases

Wenjing Zou, Yan Peng, Jing Li et al.

✦ AI-curated · Sources linked

Case in brief

A human case of Japanese encephalitis virus genotype V (JEV GV) was confirmed in China through serological testing, sequencing, and quantitative reverse transcription PCR. This case underscores the ongoing risk posed by JEV GV, which has previously been associated with viral encephalitis outbreaks in South Korea.

Diagnostic / clinical pearl

Clinicians should be aware of the potential for Japanese encephalitis virus genotype V to cause encephalitis in regions where it has not been previously reported.

Why it matters

This case emphasizes the need for vigilance regarding emerging infectious diseases and the geographic spread of known pathogens.

Source

PubMed · PMID 42811516

Published in Emerg Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.